Relapsing Remitting Multiple Sclerosis Clinical Trials
3 recruiting trials for Relapsing Remitting Multiple Sclerosis. Eligibility criteria explained in plain English.
TrialFinderData lists 3 Relapsing Remitting Multiple Sclerosis clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Every phased trial in this set is Phase 1 (1 of the listed studies); the remaining records are observational or have no phase recorded on ClinicalTrials.gov.
Research is led by Heinrich-Heine University, Duesseldorf (1), Hoffmann-La Roche (1), Queen Mary University of London (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is Anti-CD20 antibody (drug, 1 trial), followed by MS Care Platform (icobrain ms and icompanion ms), Ixazomib (NINLARO®) capsules / Matching placebo capsules.
Track Relapsing Remitting Multiple Sclerosis trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
Understanding the 'Durable Effect' Concept of B-cell Modulating Therapies
This prospective, observational clinical study aims to longitudinally assess peripheral immune cell profiles of patients with relapsing-remitting multiple sclerosis (RRMS)...
Study to Evaluate the Usability and Value of Integrated Digital Solutions in Medical Care of Participants With Multiple...
The main purpose of this study is to assess the usability and value of the multiple sclerosis (MS) care management platform in terms of improved monitoring of people with MS...
SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis
The study seeks to investigate safety and efficacy of ixazomib (NINLARO), a proteasome inhibitor, in multiple sclerosis (MS). Participants will receive either ixazomib capsules or...
Explore Other Conditions
Frequently Asked Questions
There are currently 3 clinical trials for Relapsing Remitting Multiple Sclerosis, with 3 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Relapsing Remitting Multiple Sclerosis, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Relapsing Remitting Multiple Sclerosis, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.